Issuer: CureVac / Key word: Study
CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK.
Issuer: CureVac / Key word(s): Study28.05.2024 / 13:00 CET/CESTThe issuer is solely responsible for the content of this announcement.CureVac Announces Dosing of First Participant in a Phase 2 Study in Seasonal Influenza; Development in Collaboration with GSK Phase 2 study to assess updated formulations for im.
Operator: Greetings and welcome to the CureVac Fourth Quarter and Full Year 2023 Financial Results and Business Update Conference Call. At this time, all participants are in a listen-only mode.
Investegate announcements from EQS-News: CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza (H5N1); Development in Collaboration with GSK
CureVac Announces Start of Combined Phase 1/2 Study in Avian Influenza ; Development in Collaboration with GSK finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.